CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Lexaria (LEXX) stock jumps 24% on positive CBD test results

By Kevin Donovan

20:39, 8 December 2021

Arterial stiffness
Lexaria's CBD tests show positive arterial stiffness results - Photo: Shutterstock

Lexaria Bioscience stock jumped 24.2% Wednesday, after the announcement that its cannabidiol (CBD) distribution method for treating hypertension has potentially broader applications than initially thought.

Lexaria stock jumped to a session high of $6.11 after the opening bell, from Tuesday’s $4.92 per-share closing price. Lexaria shares moved lower in the afternoon to close at $5.60 per share, up 13.8%.

Trading volume for Lexaria stock topped 12.8 million, versus the 74,266 daily average volume, according to data maintained by Nasdaq. Lexaria’s stock trades on the Nasdaq exchange under the ticker LEXX.

Positive test results

Before the market open, Kelowna, British Columbia-based Lexaria announced its DehydraTECH CBD delivery method improved arterial stiffness and alleviated hypertension during a preliminary human testing programme.

As a result, Lexaria believes DehydraTECH may potentially be used to treat a wide array of cardiovascular diseases beyond high blood pressure.

“Reducing arterial stiffness in Lexaria's recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” said Lexaria president John Docherty in a prepared statement. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”

Clinical human trials

The HYPER-H21-2 trial on 16 human subjects aged 45 to 65 with mild to moderate hypertension experienced a 23% drop in blood pressure, on average, compared to placebo. Subjects were administered three doses over 14 hours followed by a 24-hour observation period.


0.63 Price
+0.090% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


15,840.60 Price
+0.100% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

72.89 Price
-0.780% 1D Chg, %
Long position overnight fee -0.0224%
Short position overnight fee 0.0005%
Overnight fee time 22:00 (UTC)
Spread 0.030


2,018.49 Price
-0.500% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.50

All objectives of the human clinical study have been successfully completed and Lexaria will next conduct a HYPER-H21-4 trial with multiple doses administered over six weeks.

“Multiple doses over this period are expected to demonstrate additional benefits against hypertension and arterial stiffness,” the company added.

Arterial stiffness is a killer

Generalised arterial stiffness is a hallmark of normal human ageing, according to the National Institutes of Health. It can be a predictor of multiple fatal diseases in addition to hypertension, including diabetes, stroke, heart failure and atrial fibrillation.

DehydraTECH is an efficacy enhancing oral or topical lipophilic, or fat-soluble, drug payload delivery method.

DehydraTECH is protected by 18 granted patents internationally and has roughly 60 additional pending patents for use with a broad range of bioactive molecules, including antivirals, pharmaceuticals, nicotine, non-steroidal anti-inflammatory drugs as well as hemp (CBD).

The DehydraTECH delivery method increases bio-absorption, reduces onset to minutes instead of hours and reduces side effects, due to the smaller administered doses. Lexaria hopes to apply the DehydraTECH delivery method to Covid-19 antiviral drugs.

Read more: Boston Scientific buys 84% Devoro Medical stake for 9m

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading